Skip to main content
. 2023 Nov 30;14(11):786. doi: 10.1038/s41419-023-06302-0

Fig. 8. DDX5 overexpression enhances anti-tumor efficacy of sorafenib in Huh7 xenograft tumors.

Fig. 8

A DDX5 and GPX4 immunoblots of lysates from Dox-inducible Huh7-DDX5 tumors, ±Dox and SOR administration, as indicated (80 mg/kg, 5 days per week). Actin is used as a loading control. B Tumor weight for each treatment group from the indicated number of tumors. **p < 0.01 by unpaired t-test. Quantification of: C MDA (nmoles/mg tissue) and D 4-HNE (µg/mg tissue) using Huh7 xenograft tumors treated with ±DOX and SOR, as indicated. Data are expressed as mean ± SEM from eight tumors. *p < 0.05, ***p < 0.001 by unpaired t-test. (E) RT-PCR quantification of DVL1 mRNA using total RNA isolated from Dox-inducible Huh7-DDX5 tumors, ±Dox and SOR, as indicated. Data expressed as mean ± SEM from the indicated number of tumors in each group. *p < 0.05, **p < 0.01 by unpaired t-test. F Immunohistochemistry (IHC) of indicated HCCs from TMA described in Fig. 1, with DDX5 and DVL1 antibodies (Numbers indicate tumor position in TMA, Fig. S8B). Representative images at 20× magnification.